Ruxolitinib Hemifumarate is a potent JAK1 and JAK2 inhibitor indicated for the treatment of myelofibrosis and polycythemia vera, conditions characterized by the bone marrow’s impaired ability to regulate… Read more
Ruxolitinib Hemifumarate is a potent JAK1 and JAK2 inhibitor indicated for the treatment of myelofibrosis and polycythemia vera, conditions characterized by the bone marrow’s impaired ability to regulate blood cell production. This category provides comprehensive analytical tools necessary for the pharmaceutical industry, including high-quality reference standards of the active ingredient and related compounds such as the S-enantiomer, pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Laboratories rely on these materials to perform accurate impurity profiling, facilitate method validation, and ensure rigorous quality control throughout the drug development and manufacturing lifecycle. By utilizing these precise analytical standards, researchers and quality control scientists can effectively identify, quantify, and characterize potential degradants or process-related impurities, ensuring compliance with regulatory requirements and supporting the overall safety and efficacy of the final pharmaceutical product.